## **ASX ANNOUNCEMENT**



12 May 2015 www.intgold.com.au

Company Announcements Office Australian Securities Exchange Level 6, 20 Bridge Street SYDNEY NSW 2000

Via E Lodgement

# WINTER GARDEN BIOSCIENCES EXPLAINS PLANNED MASS-SCALE PRODUCTION OF HIGH PURITY AND POTENCY CANNABINOID EXTRACTS

International Goldfields Ltd (ASX:IGS) ("IGS" or the "Company") is pleased to provide an update about Winter Garden Biosciences ("Winter Garden" or "WG") operational plans for 2015/2016. WG is a Uruguayan biosciences and pharmaceutical company in which IGS has agreed to acquire an 85% interest (refer ASX announcement dated 1 May 2015).

## Mass Production and Sale of High Potency Cannabinoid Extracts

Winter Garden's primary business revenues will be generated from the production and sale of high-potency cannabinoid extracts, specifically cannabidiol (CBD) based extractions, which are in high demand due to the growing appreciation for the potential health and therapeutic benefits. These extracts can be utilised in a variety of natural forms including global beverage, health food, medicinal, powdered, and capsulated forms.

CBD's are the non-psychoactive components that directly activate various non-cannabinoid receptors and indirectly activate CB receptors. CBD's have been shown to have anti-convulsant, anti-psychotic, anti-oxidant, anti-inflammatory, neuroprotective, and immunomodulatory properties.

Winter Garden is able to use non-synthesized heirloom hemp and cannabis varieties to produce high-potency extractions, highest purity products that are quantitatively and qualitatively measured and standardised beyond any formulation currently on the market. Another important WG production characteristic is that extracts possess unaltered chemical, terpine and flavonoid profiles conferring significant additional benefits not present in synthetically produced CBDs.

Additionally, WG expects to have an average concentration of 30% CBD by weight. By comparison, North American CBD extracts average less than 20% CBD by weight due to regulatory restrictions on hemp and cannabis production. The estimated 50% advantage in potency will make Winter Garden a global industry leader in the CBD extract marketplace.

#### **BOARD**

Michael Edwards Chairman

David Tasker Director

Travis Schwertfeger Director

#### **COMPANY SECRETARY**

Jane Flegg

## REGISTERED OFFICE AND PRINCIPLE PLACE OF BUSINESS

Ground Floor, 1 Havelock Street WEST PERTH WA 6005

PO Box 684 WEST PERTH WA 6872

#### COMMUNICATION DETAILS

Telephone: +61 8 9488 5220 Facsimile: +61 8 9324 2400

Web Address: www.intgold.com.au Email Address: info@intgold.com.au

#### **AUSTRALIAN BUSINESS NUMBER**

69 099 544 680

### **SHARE REGISTRY**

Advanced Share Registry Services Pty Ltd 150 Stirling Hwy Nedlands WA 6009

## MEDIA CONTACT

Tony Dawe PPR

T: 08 9388 0944 E: tony.dawe@ppr.com.au

ASX CODE IGS



Winter Garden is fully licensed to export cannabinoid products, including its high-potency CBD extracts. The Company plans to primarily target wholesale distribution partners which have developed CBD based product lines in the United States, Canada and Europe. This includes pharmaceutical and nutraceutical companies, in addition to companies focused on the marijuana marketplace. Winter Garden will also look at making its products available to retail consumers in North America and Europe which will supplement its wholesale revenues.

Julian Strauss, the founder of Winter Garden, stated: "The funding received through the proposed acquisition with IGS allows us to immediately begin cultivating our heirloom genetics on over 20 hectares of company owned land, with annual yields from two growing seasons at over 100 kilograms per hectare."

"We believe that we will extract the highest potency, most pure and critically, non-synthetic Cannabidiol available internationally. This will disrupt the CBD marketplace, which we have seen absorbing new demand and growing exponentially in the US and European markets, at a price point of US\$100,000 per kilogram."

David Tasker, Director of IGS, stated: "The strategic acquisition represents a strong potential for large +90% margin near-term revenue inflows and consequently, significant upside potential for our shareholders. IGS is intent on expeditiously finalising this transaction and meeting its re-compliance obligations, including the funding of WG for which we have seen a very enthusiastic response to date."

Winter Garden is currently in negotiations with global CBD distribution companies regarding distribution agreements for its cannabinoid products and will update the market in due course should these negotiations proceed to a formal outcome.

For and on behalf of the board

David Tasker Director

## FOR FURTHER INFORMATION, PLEASE CONTACT:

International Goldfields Professional Public Relations

T: +61 8 9488 5220 Tony Dawe

T: +61 8 9388 0944 M: +61 405 989 743

E: info@intgold.com.au E: tony.dawe@ppr.com.au